Sodium Iodide I-131

Revenues Increased 28% in the Second Quarter; Net Cash Generation from Operations of more than $1,000,000 For The Six Months Ended June 30, 2023; June 30th Cash Balance Remains In Excess Of $3,000,000 IDAHO FALLS, Idaho, Aug. 14, 2023 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the three- and six-month periods ended June 30, 2023. Revenue for the six months ended June 30, 2023, was $6,201,700 compared to $5,242,249 for the same period in 2022. This was an overall increase of approximately 18% and was primarily the result of a significant increase in sales of radiochemical and cobalt products. Revenue for the three months ended June 30, 2023, was $3,112,165 compared to $2,434,808 for the same period in 2022, an overall increase of approximately 28%. The increase in revenue for the three-month period was largely the result of increased sales of cobalt products, which was largely attributable to the timing of sales in the period comparisons, and continued sales growth for our radiochemical division. The Company reported a net loss for the six-month period ended June 30, 2023, of $411,356 compared to a net income of $982,997 for the same period in 2022. The decrease in net income was primarily attributable to a one-time $1.8 million gain on the sale of assets during the first quarter of 2022. The Company also reported a net loss for the second quarter ended June 30, 2023, of $263,302, a slight improvement compared to a net loss of $272,048 for the same period in 2022. The net loss was largely attributable to a global shortage of raw material for the nuclear medicine segment during April 2023, temporarily increased executive salary expenses as we carried an additional officer during Mr. Bagerdjian's transition to President, and continued investment and R&D activity at a corporate level, with R&D expenses increasing more than 100% year on year. The Company's cash flow and cash position remains strong. Net cash from operating activities for the for the six-month period ended June 30, 2023, was $1,000,448 compared to a decrease of cash of $951,052 for the same period in 2022. As of June 30, 2023, cash and cash equivalents increased to $3,274,125 compared to $2,375,817 as of December 31, 2022. The following provides a summary of our current business segment performance for the three-and six-month periods ended June 30, 2023: Radiochemical Products Revenue from the radiochemical products segment increased approximately 26% for the three-month period and 16% for the six-month period ended June 30, 2023, compared to the same periods in 2022. The increase in both periods was primarily the result of continued growth in demand for our radiopharmaceutical product (generic sodium iodide I-131). Our sodium iodide radiopharmaceutical drug is used to treat thyroid cancer and diseases and we are currently the only domestic manufacturer of this important theranostic radiopharmaceutical drug product. We expect continued growth for our radiochemical segment due to continued demand and the addition of synergistic new devices and accessories to support our radiopharmaceutical product sales. Nuclear Medicine Segment Revenue from nuclear medicine products, operating as RadQual LLC, for the three months ended June 30, 2023, decreased 3% compared to the same period in 2022. Revenue from nuclear medicine products for the six months ended June 30, 2023, increased approximately 7% compared to the same period in 2022. The decrease in revenue over the three-month period was largely due to a global shortage of a key isotope raw material in April 2023. Overall, we are pleased with the six-month period results despite the shortages, and we anticipate continued growth of the nuclear medicine segment as our raw material supply has stabilized. Cobalt Products Revenue from the sale of cobalt products for the three months ended June 30, 2023, increased approximately 352% and revenue for the six-month period increased approximately 124% compared to the same period in 2022. The increase for both periods was primarily due to the timing of sales. Large volume cobalt sales typically occur on a somewhat random basis and can have a significant impact on period-to-period comparisons. The Company continues to expect an increase in cobalt sales during the second half of the year. The Company remains the only domestic manufacturer and supplier of high activity cobalt-60 sealed-source products. Shahe Bagerdjian, President of the Company, said, "We expect a steady and positive financial performance for the Company for the remainder of this year. A planned maintenance outage at our main raw material supplier in August may impact some radiochemical product sales, however sales are expected to continue to be strong in the third and fourth quarters. There are several significant cobalt sales scheduled for the second half of the year which should boost revenue performance in that segment. Overall, we continue to develop new products for our nuclear medicine reference and calibration standards division, which have received positive feedback from our customer base. We also continue to see a growing demand for our products from international customers in Latin America and Europe, where we are focused on significantly increasing our presence over the coming quarters. Overall, we believe the Company will continue to generate positive cash flow and we expect to report a strong finish to the fiscal year." About International Isotopes Inc. International Isotopes Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. INIS manufactures and supplies generic sodium iodide I-131 radiopharmaceutical drug product for hyperthyroidism and thyroid cancer. INIS manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards. The Company also manufactures Cobalt-60 sealed source products and provides contract manufacturing of various drug products as well as radioisotope API supply for clients. International Isotopes Inc. Safe Harbor Statement Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at , including its Annual Report on Form 10-K for the year ended December 31, 2022. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. FOR MORE INFORMATION, CONTACT: David Drewitz Creative Options Communications Investor and Public Relations [email protected] Phone: 972-814-5723 -END- SOURCE International Isotopes Inc.

The Company Reported A 10% Increase In Revenue And Net Income of more than $900,000 For The Six Months Ended June 30, 2022 IDAHO FALLS, Idaho, Aug. 16, 2022 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the three- and six-month periods ended June 30, 2022. Revenue for the six months ended June 30, 2022, was $5,242,249 compared to $4,752,408 for the same period in 2021. This was an overall increase of approximately 10% and was the result of a significant increase in sales of radiochemical products. Revenue for the three months ended June 30, 2022, was $2,434,808 compared to $2,759,896 for the same period in 2021, an overall decrease of approximately 12%. The decrease in revenue for the three-month period was largely the result of decreased sales of cobalt products which was largely attributable to the timing of sales in the period comparisons. The Company's net income for the six-month period ended June 30, 2022, was $982,997 compared to a net loss of $782,539 for the same period in 2021. The increase in net income was attributable to a $1.8 million gain on the sale of assets during the first quarter and by continued increases in radiochemical sales. The Company did report a net loss for the second quarter ended June 30, 2022, of $272,048, compared to a net loss of $181,387 for the same period in 2021. The net loss was largely attributable to the lack of cobalt product sales during the second quarter. The following provides a summary of our current business segment performance for the three-and six-month periods. Revenue from the radiochemical products segment increased approximately 12% for the three-month period and 59% for the six-month period ended June 30, 2022, compared to the same periods in 2021. The increase in both periods was primarily the result of growth in our customer base and increased customer purchasing volumes. Our sodium iodide drug is used to treat thyroid cancer and diseases of the thyroid and we are currently the only domestic supplier of this important drug product. Revenue from nuclear medicine products, operating as RadQual LLC, for the three months ended June 30, 2022, increased less than 1% compared to the same period in 2021. Revenue from nuclear medicine products for the six months ended June 30, 2022, decreased approximately 8% compared to the same period in 2021. The Company believes the decrease in revenue over the six-month period and smaller than hoped increase over the three-month period are both attributable to the lingering impact of COVID-19 on patient nuclear medicine treatment and imaging procedures. Revenue from the sale of cobalt products for the three months ended June 30, 2022, decreased approximately 83% and revenue for the six months period decreased approximately 61% compared to the same period in 2021. The decrease for both periods was primarily due to the timing of sales. Large volume cobalt sales typically occur on a somewhat random basis and can have a significant impact on period-to-period comparisons. The Company continues to expect a significant increase in cobalt sales during the second half of the year. Steve Laflin, President, and CEO of the Company, said, "We continue to expect very positive financial performance for the Company for the remainder of this year. Radiochemical product sales are expected to continue to be strong in the third and fourth quarter. There are several significant cobalt sales scheduled for the second half of the year which should boost revenue performance in that segment. And, steps we are taking to strengthen our sales force, marketing presence, and conduct special product promotions should help the nuclear medicine reference and calibration standards improve sales as well. We also believe the lingering negative impact COVID-19 will continue to dissipate. Overall, we believe the Company will continue to generate positive cash flow and we expect to report a strong finish to, and overall profit for, the calendar year." About International Isotopes Inc. International Isotopes Inc. manufactures a wide range of calibration and reference standards for nuclear medicine, generic sodium iodide I-131 drug product for hyperthyroidism and thyroid cancer, Cobalt-60 sealed source products, and provides contract manufacturing of various drug products for clients. International Isotopes Inc. Safe Harbor Statement Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements with respect to future performance of the Company's business segments and the impact that COVID-19 will, or will not have on our business performance and revenue growth. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at , including its Annual Report on Form 10-K for the year ended December 31, 2021. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. FOR MORE INFORMATION, CONTACT: David Drewitz Creative Options Communications Investor and Public Relations david@creativeoptionscommunications.com Phone: 972-814-5723 View original content: SOURCE International Isotopes Inc. Company Codes: OTC-PINK:INIS, OTC-BB:INIS